T raditionally, definitive treatment of achalasia has been a surgical Heller myotomy (HM) and pneumatic dilation (PD). Long-term symptomatic response after HM can be achieved in more than 90% of patients with a low complication rate of approximately 5%. However, recurrent or persistent symptoms occur in approximately 10% to 20% of patients. 1, 2 In patients with recurrent or persistent symptoms after HM, treatment options have been repeat HM 3, 4 or PD. 5, 6 Peroral endoscopic myotomy (POEM) has gained acceptance as an endoscopic alternative to surgical myotomy for the treatment of achalasia. A number of clinical studies have reported response rates of more than 80% to 90% after POEM. [7] [8] [9] Recently, POEM has been described as a rescue endoscopic therapy for patients who failed HM, with symptomatic improvement in 90% of patients and a low rate of adverse events. 4, [10] [11] [12] However, the data on efficacy and safety of POEM in this setting have been limited to few single-center small series.
Given the previously reported high rate of treatment success and excellent safety profile, we hypothesized that clinical outcomes are comparable between patients with and without a history of HM. The primary aim of this study was to compare the efficacy of POEM in achalasia patients with recrudescent or persistence of symptoms after HM and those who never received HM. Secondary outcomes are rates of technical success of POEM, procedure-related adverse events, and development of post-POEM reflux.
Methods

Retrospective Cohort Design
We reviewed records of all adult patients (age, !18 y) with achalasia and Eckardt scores (ES) of 3 or higher who underwent POEM between December 2009 and September 2015 at 13 tertiary-care centers.
Exposure of Interest
History of surgical HM was the exposure of interest. Patients who previously had undergone HM were considered exposed to HM. On the contrary, patients with no history of prior HM were considered unexposed to HM or non-HM.
Matching
To ensure balanced distribution of some potential confounders, we matched exposure groups by age (AE5 y), achalasia subtypes (types I and II or type III or unspecified subtype), and baseline ES (stage II [ES [4] [5] [6] or stage III [ES > 6]). 13 The non-HM group was selected randomly without replacement to match each HM case on a 1:1 basis. A number of patients underwent conventional manometry before highresolution manometry was available. These patients were classified as unspecified achalasia subtype.
Exclusion Criteria
We excluded patients with a history of prior POEM, patients with esophageal cancer, and patients with a history of esophageal surgery (other than HM).
This study was approved by the institutional review board for human research at each institution.
Data Collection
Clinical and procedural data were collected, including manometric data (achalasia subtype according to Chicago classification using high-resolution manometry, integrated relaxation pressure [IRP]), previous endoscopic treatments (PD using the balloon !30 mm or injection of botulinum toxin), endoscopic data (length of myotomy, orientation of myotomy), procedure-related adverse events, postprocedural symptoms, and results of upper endoscopy after POEM, when available.
Postoperative Care and Clinical Follow-Up Evaluation
The patients were admitted for hospital observation. A water-soluble esophagram was obtained before initiation of an oral diet. All patients were continually followed up by in-person clinic visits and telephone interviews. Upper endoscopy, esophageal manometry, and pH study were obtained according to each center's follow-up protocol.
Definition
The primary outcome was clinical response, which was defined by a decrease in ES to 3 or less. 13 Adverse events were graded according to the American Society for Gastrointestinal Endoscopy lexicon.
14 Symptomatic reflux was defined as self-reported heartburn and/or regurgitation. The severity of esophagitis was classified into 4 grades according to the Los Angeles Classification.
Statistical Analyses
Technical success, clinical success, and adverse events were compared between the 2 groups. Categoric data were evaluated by the chi-square test. Continuous variables were compared using the Student t test or Mann-Whitney U analyses as appropriate. A logistic regression model was performed to study the factors associated with treatment failure. Multivariate models were planned using variables that were significant at a P value less than .10 in the univariate analysis. Further conditional logistic regression was performed to take matching into account (data not shown). The results did not change whether we used conditional or unconditional logistic regression and we opted to present unconditional logistic regression. Two-sided P values less than .05 were considered significant.
Results
A total of 180 patients (98 females (54%); mean age, 54 AE 16 y) were included in this study. Table 1 ). The median duration of symptom recurrence was 5.0 years (interquartile range [IQR], 1.7-10 y) before rescue POEM. The median interval between the first HM and rescue POEM was 7.9 years (IQR, 2.7-13 y). The most common reason for failed HM was thought to be incomplete prior myotomy (74%).
Of 180 patients, 90 patients were in the HM group and 90 patients were in the non-HM group. Patient and procedure details are shown in Table 1 . There was no difference between the groups in baseline demographics, ES, and 4-second integrated relaxation pressure (4sIRP). The average interval between the previous HM and POEM procedure in the HM group was 5 years (IQR, 2-11 y). The HM group had a higher proportion of patients with prior PD (44% vs 26%; P ¼ .01). The length of myotomy was similar between the 2 groups. There was no significant difference between the HM group and the non-HM group in the length of hospital stay (3.54 AE 1.7 vs 3.59 AE 2.5 d; P ¼ .87). 
Technical Success
Clinical Success After Peroral Endoscopic Myotomy
Of 180 patients, 167 (93%) had at least 3 months of follow-up data after POEM (Table 3 ). These 167 patients included 85 (94%) in the HM group and 82 (91%) in the non-HM group. The median follow-up period after POEM was 8.5 months (IQR, 1.3-18.5 mo) in the non-HM group and 9 months (IQR, 4-14 mo) in the HM group (P ¼ .89). Clinical response (ES 3) was 81% (69 of 85) in the HM group, which was significantly lower than that of the non-HM group (94%) (77 of 82) (P ¼ .01). The mean post-POEM ES also was higher in the HM group when compared with the non-HM group (2.12 AE 2.5 vs 1.06 AE 1.2; P ¼ .001). In the HM group, the mean 4s IRP was 27.9 AE 21 mm Hg before POEM compared with a post-POEM mean 4s IRP of 6.2 AE 4.4 mm Hg (P < .001). In the non-HM group, the mean 4s IRP was 23.3 AE 10.2 mm Hg before POEM compared with a post-POEM mean 4s IRP of 7.5 AE 4.1 mm Hg (P < .001). There was no significant difference in the post-POEM 4s IRP and lower esophageal sphincter resting pressure between the HM group and the non-HM group (P ¼ .25 and .10, respectively). The characteristics of the 16 patients in the HM group with clinical failure after POEM are summarized in Supplementary Table 3 .
On univariable analysis ( (Table 5) showed that prior HM (adjusted OR, 3.02; 95% CI, 1.02-8.92; P ¼ .04) was associated independently with clinical failure after POEM. Prior PD was associated marginally with poor clinical response to the POEM procedure (adjusted OR, 2.64; 95% CI, 0.99-7.04; P ¼ .05).
Adverse Events
A total of 20 procedure-related adverse events occurred in 19 patients (10.4%) ( Table 2 ); 14 were rated as mild, 4 were rated as moderate, and 1 was rated as severe. There were no deaths related to POEM. The most common adverse event was inadvertent mucosotomy, which occurred in 7 patients (4%). One severe adverse event (esophageal leak and mediastinitis) occurred in the HM group. This patient underwent video-assisted thoracoscopic surgery for drainage of the mediastinum. Other reported adverse events included 5 symptomatic pneumoperitoneum, 1 symptomatic pleural effusion, 1 aspiration pneumonia, 1 symptomatic pneumothorax, 1 delayed bleeding, 2 symptomatic subcutaneous emphysema, and 1 submucosal hematoma. There were no significant differences in adverse event rates between the 2 groups (7 [8%] in the HM group and 12 [13%] in the non-HM group; P ¼ .23). For the HM group and the non-HM group, respectively, the rates of mild (5% vs 10%; P ¼ .28) and moderate (1% vs 3%; P ¼ .34) adverse events were similar.
Postprocedure Reflux
Data on post-POEM symptomatic reflux and the presence of reflux esophagitis were available in 146 and 85 patients, respectively. Post-POEM symptomatic reflux was reported in 30% (21 of 70) of patients in the HM group. There was no significant difference in post-POEM symptomatic reflux between the 2 groups (non-HM group, 32%; P ¼ .85). Reflux esophagitis was noted in 44% of patients (18 of 41) in the HM group, which was similar to the non-HM group (52%) (P ¼ .55). Most of these patients had only Los Angeles grade A esophagitis (Table 3) .
Discussion
In this large multicenter study that evaluated the clinical outcomes of POEM in achalasia patients who did not respond to prior HM, we found that POEM for failed prior HM had a high technical success rate of 98%. The clinical success of patients with prior HM was 81%, and was lower than that for the patients without a history of surgical myotomy. The safety profile of POEM was comparable with that of patients without a history of HM.
PD and redo HM have been the 2 main therapeutic options for achalasia patients who failed prior HM. Previous studies have reported that the success rates of PD in patients who failed prior HM ranged between 50% and 89%. 5, 6, 15 The main disadvantage of PD is short durability of this treatment. The patients need repeat PD for symptom relapse in approximately 16% to 45% in 2 years. 5, 6 In addition, each procedure put the patients at risk for potentially serious adverse events related to PD, such as esophageal perforation or aspiration.
Redo surgical myotomy commonly is performed for treatment of recurrent achalasia after initial HM. Treatment success of redo HM in patients with recurrent/ persistent symptoms after HM appears to be lower than the first HM and has ranged between 73% and 89%. [16] [17] [18] Because of the presence of adhesions and fibrosis from the previous surgery, redo HM is technically challenging and a high rate of gastrointestinal perforation has been reported (1.5%-20%). 19 Recently, POEM has been described as a rescue endoscopic therapy for patients with persistent or recurrent symptoms after HM for achalasia. Previous studies have reported very high clinical success rates (92%-100%) of POEM in the setting of prior HM. [10] [11] [12] POEM can be performed safely even in the presence of prior fundoplication. 10, 11 In a study by Onimaru et al 10 including 11 patients who had persistent or recurrent achalasia after surgical myotomy, all patients underwent PD as the first-line rescue treatment. The PD alone was effective in only 1 patient. The remaining 10 patients had unsatisfactory results and subsequently underwent POEM. A significant reduction in ES also was achieved in all patients. Zhou et al 12 studied 12 patients with failed prior HM who underwent POEM. Treatment success (ES 3) was achieved in 11 of 12 patients (92%). Vigneswaran et al 11 studied 5 patients with recurrent/ persistent symptoms after laparoscopic HM who underwent redo myotomy with POEM. All patients showed improvement of their symptoms. The mean ES decreased from 6.8 before POEM to 0.6 after POEM (P ¼ .0004). Our clinical success was somewhat lower than that reported in the previous studies. This could be partially owing to the high proportion of patients in the HM group who had failed prior PD in the current study. We also found that prior HM and prior PD were associated with decreased clinical response to POEM. Previous PD or HM could cause a fibrotic reaction at the lower esophageal sphincter and lead to difficulties in dissecting different esophageal wall planes and thus compromise treatment outcomes.
The rate of POEM-related adverse events in the HM group in our study was similar to the non-HM group and is consistent with the published literature in patients without prior HM, which ranges between 3% and 20%. 8, 20 Postoperative gastroesophageal reflux and reflux esophagitis occurred with similar frequency in patients with prior HM and in non-HM patients. These findings support an acceptable safety profile of the POEM procedure in patients with a prior surgical myotomy.
There are some advantages of POEM over redo surgical myotomy for failed prior HM. POEM is associated with shorter surgical time, less blood loss and postprocedural pain, and a faster return to activities of daily living as compared with surgical myotomy. 21, 22 Endoscopists easily can select orientation of myotomy via POEM, whereas the preferred direction of myotomy could be difficult to access in surgery. 10 Moreover, POEM allows access to the entire esophageal body. Thus, longer myotomy, when needed (eg, type III achalasia), can be performed in the proximal esophagus, although this may not be possible through a laparoscopic HM. These advantages along with results from the current study suggest that POEM may be a more preferred therapeutic option in patients with a failed initial surgical myotomy.
The common causes of failed HM are incomplete myotomy at the index surgery, early healing of myotomy by fibrosis, and, less commonly, esophageal diverticulum, peptic stricture, and tight fundoplication. 23, 24 A thorough evaluation of potential causes of treatment failure is imperative because further plans depend on the cause for treatment failure. For instance, for patients with symptom relapse or failure to respond to surgical myotomy as a result of incomplete myotomy and/or myotomy fibrosis, POEM is likely to be effective. On the other hand, when the cause of persistent symptoms after surgical myotomy is tight fundoplication, a redo fundoplication should be recommended.
The strengths of this study included a retrospective cohort study that involved a large number of patients with failed prior HM and reported comparative data with a non-HM group. Because this was a retrospective study, the results of our study could be influenced by selection bias. We attempted to minimize this bias by adjusting the odds ratio for clinical failure after POEM in multivariable analysis. Moreover, the median follow-up duration of this study was only 8.5 months, and follow-up protocols were not standardized and varied among different centers. To evaluate long-term outcomes of patients undergoing POEM after failed prior HM, intensive follow-up protocol over a period of several years is required. In summary, POEM appears to be safe and effective for achalasia patients who failed prior HM with excellent midterm symptom relief in most patients. Although the rate of clinical success in patients with prior HM is lower than in those without prior HM, the safety profile of POEM is comparable with that of patients with no prior HM. Further studies with longer follow-up data are needed to determine the durability and long-term benefit of POEM in this subgroup of patients.
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